The Trump administration’s push to get more Medicare Shared Savings Program (MSSP) ACOs to take on downside risk is having an effect, but there are still many nontakers.
The Trump administration’s push to get more Medicare Shared Savings Program (MSSP) ACOs to take on downside risk is having an effect, but there are still many nontakers.
According to tallies in an analysis published on the Health Affairs blog last month, 53% of the 139 MSSP ACOs that migrated out of the regular MSSP program last year into the administration’s Pathways to Success program took on downside risk. That makes sense because the Pathways program is designed to encourage ACOs to take on downside risk. But a greater proportion (309 out of 514, or 60%) of the MSSP ACOs stayed in the legacy program and only 17% of those ACOs took on downside risk.
Trump administration health officials — and a number of experts outside the administration — have argued that the ACOs will realize their value-base care potential only if they take on downside risk, the shorthand way of saying that penalties would be assessed if the ACO exceeds financial benchmarks.
The analysis was conducted by Mark McClellan, M.D., Ph.D., director the Duke-Margolis Center for Health Policy at Duke University, and his colleagues.
McClellan, who was FDA commissioner and CMS administrator during the George W. Bush administration, and his co-authors say cost and quality metrics for ACOs this year will be “muddled” because of the COVID-19 pandemic and uncertainty about the effects of the adjustments CMS has made in the program. They note, though, that the dire scenario of an exodus of ACOs because of the Pathway of Success rules didn’t happen last year
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
Illuminating the Dark Corners of HIV-1 Persistence: Insights from Nonsuppressible Viremia
December 4th 2023Some people still have low levels of HIV despite taking antiretroviral therapy as prescribed and lacking any indications of drug resistance. Understanding why could yield new strategies for dealing with HIV.
Read More